Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 27, Issue 8, Pages 1451-1457
Publisher
Springer Science and Business Media LLC
Online
2021-08-13
DOI
10.1038/s41591-021-01455-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
- (2021) Günter U Höglinger et al. LANCET NEUROLOGY
- Immunotherapy in progressive supranuclear palsy
- (2020) Pavan A. Vaswani et al. CURRENT OPINION IN NEUROLOGY
- Cryo-EM structures of tau filaments
- (2020) Sjors HW Scheres et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Clinical Conditions “Suggestive of Progressive Supranuclear Palsy”—Diagnostic Performance
- (2020) Max‐Joseph Grimm et al. MOVEMENT DISORDERS
- Characterization of tau binding by gosuranemab
- (2020) Richelle Sopko et al. NEUROBIOLOGY OF DISEASE
- Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy
- (2019) Farwa Ali et al. MOVEMENT DISORDERS
- Motor, cognitive and behavioral differences in MDS PSP phenotypes
- (2019) Marina Picillo et al. JOURNAL OF NEUROLOGY
- Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial
- (2019) Adam L Boxer et al. LANCET NEUROLOGY
- Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?
- (2019) Ali Shoeibi et al. PARKINSONISM & RELATED DISORDERS
- Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy
- (2018) Ali Shoeibi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Tau Spreading Mechanisms; Implications for Dysfunctional Tauopathies
- (2018) Almudena Fuster-Matanzo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tau Kinetics in Neurons and the Human Central Nervous System
- (2018) Chihiro Sato et al. NEURON
- Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau
- (2018) Jean-Philippe Courade et al. ACTA NEUROPATHOLOGICA
- Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
- (2018) Sara Hall et al. Scientific Reports
- Mechanisms of Cell-to-Cell Transmission of Pathological Tau
- (2018) Garrett S. Gibbons et al. JAMA Neurology
- Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches
- (2017) Adam L Boxer et al. LANCET NEUROLOGY
- Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
- (2017) Günter U. Höglinger et al. MOVEMENT DISORDERS
- Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?
- (2017) Jennifer L. Whitwell et al. MOVEMENT DISORDERS
- Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials
- (2017) Günter U. Höglinger et al. MOVEMENT DISORDERS
- Which ante mortem clinical features predict progressive supranuclear palsy pathology?
- (2017) Gesine Respondek et al. MOVEMENT DISORDERS
- Extracellular Tau and Its Potential Role in the Propagation of Tau Pathology
- (2017) Kaoru Yamada Frontiers in Neuroscience
- Unique pathological tau conformers from Alzheimer’s brains transmit tau pathology in nontransgenic mice
- (2016) Jing L. Guo et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy
- (2016) Maria Stamelou et al. MOVEMENT DISORDERS
- Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy
- (2016) Richard M. Tsai et al. PARKINSONISM & RELATED DISORDERS
- Human secreted tau increases amyloid-beta production
- (2015) Jessica Bright et al. NEUROBIOLOGY OF AGING
- Invited review: Neuropathology of tauopathies: principles and practice
- (2015) G. G. Kovacs NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale
- (2015) Pablo Martínez-Martín et al. PARKINSONISM & RELATED DISORDERS
- Divergent CSF alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy
- (2014) D. Wagshal et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial
- (2014) Adam L Boxer et al. LANCET NEUROLOGY
- A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy
- (2014) Eduardo Tolosa et al. MOVEMENT DISORDERS
- The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases
- (2014) Gesine Respondek et al. MOVEMENT DISORDERS
- Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies
- (2014) David W. Sanders et al. NEURON
- Progressive Supranuclear Palsy
- (2014) Lawrence Golbe SEMINARS IN NEUROLOGY
- The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Utility in Detection and Characterization of Mild Cognitive Impairment due to Alzheimer's Disease
- (2013) S. Karantzoulis et al. ARCHIVES OF CLINICAL NEUROPSYCHOLOGY
- Modeling trajectories of regional volume loss in progressive supranuclear palsy
- (2013) Keith A. Josephs et al. MOVEMENT DISORDERS
- Accuracy of the national institute for neurological disorders and stroke/society for progressive supranuclear palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy
- (2013) Gesine Respondek et al. MOVEMENT DISORDERS
- Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
- (2013) Jere E. Meredith Jr. et al. PLoS One
- Brain homogenates from human tauopathies induce tau inclusions in mouse brain
- (2013) Florence Clavaguera et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Parkinson's Disease and Parkinsonism: Neuropathology
- (2013) D. W. Dickson Cold Spring Harbor Perspectives in Medicine
- Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders
- (2012) Sara Hall et al. ARCHIVES OF NEUROLOGY
- Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy
- (2011) Günter U Höglinger et al. NATURE GENETICS
- Visual signs and symptoms of progressive supranuclear palsy
- (2010) Richard A Armstrong Clinical and Experimental Optometry
- Neuropathology of variants of progressive supranuclear palsy
- (2010) Dennis W Dickson et al. CURRENT OPINION IN NEUROLOGY
- Psychometric Properties of Activity, Self-Efficacy, and Quality-of-Life Measures in Individuals with Parkinson Disease
- (2010) Vanina Dal Bello-Haas et al. Physiotherapy Canada
- LEAP: Learning embeddings for atlas propagation
- (2009) Robin Wolz et al. NEUROIMAGE
- Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
- (2008) Gilbert Bensimon et al. BRAIN
- The Potential for -Structure in the Repeat Domain of Tau Protein Determines Aggregation, Synaptic Decay, Neuronal Loss, and Coassembly with Endogenous Tau in Inducible Mouse Models of Tauopathy
- (2008) M.-M. Mocanu et al. JOURNAL OF NEUROSCIENCE
- Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells
- (2008) A. Gómez-Ramos et al. MOLECULAR AND CELLULAR NEUROSCIENCE
- Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More